A clinical study of free T3 in breast cancer and benign breast tumours
DOI:
https://doi.org/10.18203/2349-2902.isj20175894Keywords:
Breast carcinoma, Chemiluminescence immune assay, Free T3Abstract
Background: The aim of the study was to evaluate the presence of Free T3 in women with breast cancer or benign breast tumours, and to analyse a possible relationship between FT3 and these two groups of breast diseases with emphasis to laboratory findings.
Methods: Free T3 levels of 87 women hospitalized were prospectively analyzed, using an Post hoc Tukey HSD for normally distributed continuous data, chi-square test for comparison.
Results:There was no significant association of Free T3 levels in breast cancer and benign breast tumours.
Conclusions: The association between free T3 and breast tumors was evaluated in this study. Free T3 values were not statistically significant in patients with breast cancer and benign breast tumors depicting there is no association of Free T3 and risk of breast carcinoma. However, these data must be confirmed in large patient cohorts and long duration follow-up.
Metrics
References
Bland KI, Beenken SW, Copeland EE. Chapter 16 The Breast, F. Brunicardi, Dana Anderson, Timothy Billiar David Dunn, John Hunder, Raphael E. Pollock, editors Schwartz’s principles of surgery. 8th Edition. McGrow-Hill professional; 2004:344-368.
Goldman MB. Thyroid diseases and breast carcinoma. Epidemiol Rev. 1990;12:16-28.
Lemaire M, Baugnet-Mahieu L. Nuclear thyroid hormone receptors in human cancer tissues. Anticancer Res. 1986;6:695-700.
Nogueira CR, Brentani MM. Triiodothyronine mimics the effects of estrogen in breast cancer cell lines. J Steroid Biochem Mol Biol. 1996;59:271-9.
Garcia-Silva S, Aranda A. The Thyroid Hormone Receptor Is a Suppressor of ras-Mediated Transcription, Proliferation, and Transformation. Molecular and Cellular Biology. 2004;24(17):7514-23.
Selliti D, Yueh-Chu L, Tseng, Latham KR. Nuclear thyroid hormone receptors in C3H/HeN mouse mammary glands and spontaneous tumors. Carcinoma Res. 1983;43:1030-8.
Paul M. Yen Physiological and Molecular Basis of Thyroid Hormone Action. Physiological Reviews. July2001;81(3).
Ming-Li H, Horng-Heng J. Cell Growth Effects of triodothyromome and Expression of Thyroid Harmone Receptor in Prostate Carcinoma Cells Journal of Andrology. 2005;26(3).
Lai LC. Role of steroid hormones and Growth factors in breast carcinoma. Clinical Chemistry and Laboratory Medicine. 2002;40(10):969-74.
Jensen EV, Cheng G, Saji S, Makela S, Noorden SV, Wahlstrom T, et al. Estrogen receptors and proliferation markers in primary and recurrent breast carcinoma. Proceedings of the National Academy of Sciences, USA. 2001;98:15197-202.
Neville MC, McFadden TB, Forsyth I. Hormonal regulation of mammary differentiation and milk secretion. Journal of Mammary Glad Biology and Neoplasia. 2002;1:49-66.
Silva JM, Dominguez G. Expression of thyroid hormone receptor/erbA genes is altered in human breast carcinoma. Oncogene. 2002;21:4307-16.
Morgan A, Dellovade TL, Plaff W. Effect of thyroid hormones and Behavior. 2000;37:15-22.
Martinez-Iglesias O, Garcia-Silva S, Regadera J, Aranda A. Hypothyroidism enhances tumor invasiveness and metastasis development. PLoS One. 2009;4:e6428.
Reddy A. Hypothyroidism: A possible risk factor for liver carcinoma in patients with no known underlying cause of liver disease. Clin Gastroentero Hepato. 2007Jan;5(1):118-23.
Smyth PA. The thyroid, iodine and breast carcinoma. Breast Carcinoma Res. 2003;5:235-8.
Changxue LU, Sheue-Yabb C. Thyroid hormone receptors regulate adipogenesis and carcinogenesis via crosstalk signaling with peroxisome proliferator-activated receptors J of Mol End. 2010;44:143-54
Downloads
Published
How to Cite
Issue
Section
